UCBMEX:UCBN 85 ROA % is 12.08% as of Dec. 2025, which is 75% above its 10-year median of 6.91. GuruFocus rates MEX:UCBN with a GF Score™ of 85/100 and a GF Value™ of MXN1,417.06. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, UCB ranks better than 91.49% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. UCB's annualizedNet Income for the quarter that ended in Dec. 2025 was MXN45,668 Mil.
UCB's average Total Assets over the quarter that ended in Dec. 2025 was MXN378,052 Mil. Therefore, UCB's annualized ROA % for the quarter that ended in Dec. 2025 was 12.08%.
The historical rank and industry rank for UCB's ROA % or its related term are showing as below:
MEX:UCBN'
s ROA % Range Over the Past 10 Years
Min: 2.18 Med: 6.91 Max: 8.87
Current: 8.87
During the past 13 years, UCB's highest ROA % was 8.87%. The lowest was 2.18%. And the median was 6.91%.
MEX:UCBN's ROA % is ranked better than 91.49% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs MEX:UCBN: 8.87
UCB (MEX:UCBN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
UCB ROA % Related Terms
UCB ROA % Historical Data
* Premium members only.
The historical data trend for UCB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UCB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's ROA % distribution charts can be found below:
* The bar in red indicates where UCB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
UCB (MEX:UCBN) has a ROA % of 12.08% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on UCB and its competitors. This is 75% above median its historical median of 6.91. Over the past decade, UCB's ROA % has ranged from 2.18 to 8.87. According to the industry distribution chart, UCB ranks #121 out of 1422 companies in the Biotechnology industry, placing it in the top 8.5%.
Is UCB's ROA % too high?
UCB's current ROA % of 12.08% is 75% above median its 10-year median of 6.91. Over the past 10 years, this metric has ranged from a low of 2.18 to a high of 8.87. Based on the distribution chart, UCB ranks #121 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does UCB's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #121 out of 1422 companies for ROA %. This places UCB in the top 9% of its industry — outperforming the majority of peers. Historically, UCB's own ROA % has ranged from 2.18 to 8.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on UCB and its competitors. UCB's current ROA % is 12.08%, which is 75% above median its own 10-year median of 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current ROA % of 12.08%. The stock's GF Value™ is MXN1,417.06, compared to a current price of MXN1,692.27 — trading 19.4% above its estimated fair value. The current ROA % is 12.08%, which is 75% above median its 10-year median of 6.91. UCB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For UCB (MEX:UCBN), the current ROA % is 12.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.
Key valuation signals for MEX:UCBN:
ROA %: 12.08% (75% above median its 10-year median of 6.91)
GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score
Get the complete analysis for MEX:UCBN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
